Table 2 TOP5 Pathways with adjusted p-value below 0,001 obtained from Enricher using the Reactome 2016 pathway. Resistant cell lines are compared with the isogenic parental control cells
From: Association of tamoxifen resistance and lipid reprogramming in breast cancer
Cell line | Term | Adjusted p-value | Overlap |
|---|---|---|---|
T47D Tam1 | Cholesterol biosynthesis | 1,49E-04 | 11/23 |
Platelet activation, signaling and aggregation | 1,49E-04 | 41/253 | |
Platelet degranulation | 1,49E-04 | 24/105 | |
Activation of gene expression by SREBF (SREBP) | 1,49E-04 | 14/42 | |
Response to elevated platelet cytosolic Ca2+ | 1,49E-04 | 24/110 | |
T-47D Tam2 | Cholesterol biosynthesis | 1,28E-07 | 13/23 |
Metabolism of lipids and lipoproteins | 1,27E-05 | 78/659 | |
Activation of gene expression by SREBF (SREBP) | 4,21E-05 | 14/42 | |
Platelet activation, signaling and aggregation | 2,06E-04 | 37/253 | |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 2,06E-05 | 15/55 | |
MCF-7 Tam1 | Cell Cycle | 8,40E-13 | 96/566 |
M Phase | 1,80E-12 | 59/268 | |
Mitotic Cell Cycle | 2,93E-12 | 82/462 | |
RHO GTPase Effectors | 7,30E-11 | 54/255 | |
Signaling by Rho GTPases | 1,27E-09 | 65/367 | |
ZR-75-1 Tam1 | MHC class II antigen presentation | 3,45E-04 | 9/103 |
Mitotic Cell Cycle | 6,60E-04 | 17/462 | |
Resolution of Sister Chromatid Cohesion | 8,75E-04 | 8/99 | |
BT-474 Tam1 | Axon guidance | 7,60E-04 | 23/515 |
Non-integrin membrane-ECM interactions | 7,60E-04 | 7/42 | |
BT-474 Tam2 | Diseases of glycosylation | 3,54E-06 | 13/88 |
Diseases associated with O-glycosylation of proteins | 3,68E-04 | 11/62 | |
O-linked glycosylation | 1,83E-05 | 13/110 | |
Defective GALNT12 causes colorectal cancer 1 (CRCS1) | 5,07E-05 | 6/18 | |
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) | 5,07E-05 | 6/18 |